P1231: IMPACT OF ARID1A AND TP53 MUTATIONS IN PEDIATRIC REFRACTORY OR RELAPSED MATURE B-CELL LYMPHOMA TREATED WITH CAR-T CELL THERAPY

P1231: IMPACT OF ARID1A AND TP53 MUTATIONS IN PEDIATRIC REFRACTORY OR RELAPSED MATURE B-CELL LYMPHOMA TREATED WITH CAR-T CELL THERAPY

Bibliographic Details
Main Authors:	Qinlong Zheng, Yang LI, Yang Liu, Keyan Yang, Ling Jin, Jing Yang, Shuang Huang, Ying Liu, Rong Liu, Wei Liu, Ansheng Liu, Yonghong Zhang
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971816.55423.e3

Similar Items

Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
by: Yang Li, et al.
Published: (2023-11-01)

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
by: Qi Zhang, et al.
Published: (2023-03-01)

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
by: Jan Mueller, et al.
Published: (2024-02-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

TP53 in Myelodysplastic Syndromes
by: Yan Jiang, et al.
Published: (2021-10-01)

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
by: Wei Liu, et al.
Published: (2024-04-01)

S110: A NOVEL AND SUCCESSFUL CD7 GENE KNOCKOUT CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY T-CELL HEMATOLOGIC MALIGNANCIES
by: J. Yang, et al.
Published: (2022-06-01)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
by: Songmi Wang, et al.
Published: (2023-01-01)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
by: Melania Tesio
Published: (2023-02-01)

Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
by: Edit Porpaczy, et al.
Published: (2021-11-01)

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
by: Wenjie Zhang, et al.
Published: (2024-04-01)

Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma
by: Ningwen Li, et al.
Published: (2024-02-01)

Current insights into the regulation of programmed cell death by TP53 mutation in cancer
by: Yali Su, et al.
Published: (2022-10-01)

Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
by: Xing-yu Cao, et al.
Published: (2023-07-01)

Construction and Validation of an Immune-Related Prognostic Model Based on TP53 Status in Colorectal Cancer
by: Xiaojuan Zhao, et al.
Published: (2019-11-01)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
by: Peiling Zhang, et al.
Published: (2022-10-01)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
by: Yinqiang Zhang, et al.
Published: (2023-04-01)

Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
by: Wen Lei, et al.
Published: (2024-01-01)

CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
by: Zhihui Li, et al.
Published: (2023-01-01)

TP53 Mutations in Esophageal Squamous Cell Carcinoma
by: Leqi Zhong, et al.
Published: (2023-09-01)

Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review
by: Satchie Sakamoto, et al.
Published: (2024-01-01)

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
by: Troy J. Kenkel, et al.
Published: (2023-10-01)

PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients
by: Ming Chen, et al.
Published: (2022-12-01)

Corrigendum: Current insights into the regulation of programmed cell death by TP53 mutation in cancer
by: Yali Su, et al.
Published: (2022-11-01)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
by: Wei Li, et al.
Published: (2023-05-01)

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
by: Peihao Zheng, et al.
Published: (2023-08-01)

CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human studyResearch in context
by: Xibin Xiao, et al.
Published: (2024-04-01)

Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells
by: Junpeng Huang, et al.
Published: (2023-01-01)

Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy
by: Lea Naomi Eder, et al.
Published: (2023-01-01)

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
by: Junfang Yang, et al.
Published: (2023-08-01)

CRISPR screens are feasible in TP53 wild‐type cells
by: Kevin R Brown, et al.
Published: (2019-08-01)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
by: Stephen L. Abrams, et al.
Published: (2022-02-01)

Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease
by: Jie Zhao, et al.
Published: (2024-04-01)

P1206: GASTROINTESTINAL BLEEDING SIGNIFICANTLY REDUCED THE EFFICACY AND SURVIVAL OF CD19 CAR-T CELL THERAPY IN PATIENTS WITH GASTROINTESTINAL TRACT INVOLVEMENT OF REFRACTORY/RELAPSED B-CELL LYMPHOMA
by: L. Ma, et al.
Published: (2022-06-01)

Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
by: Ernst, M, et al.
Published: (2021)

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia
by: Lanlan Zhou, et al.
Published: (2022-10-01)

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
by: Hao Xu, et al.
Published: (2023-03-01)

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer
by: Haoyu Lyu, et al.
Published: (2019-01-01)

Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
by: Tuoen Liu, et al.
Published: (2017-01-01)